Section for Studies on Host-Immune Response, National Cancer Center Research Institute, Chuo-ku, Tokyo, Japan.
Gene Ther. 2009 May;16(5):669-80. doi: 10.1038/gt.2009.1. Epub 2009 Feb 19.
A conditionally replicative adenovirus is a novel anticancer agent designed to replicate selectively in tumor cells. However, a leak of the virus into systemic circulation from the tumors often causes ectopic infection of various organs. Therefore, suppression of naive viral tropism and addition of tumor-targeting potential are necessary to secure patient safety and increase the therapeutic effect of an oncolytic adenovirus in the clinical setting. We have recently developed a direct selection method of targeted vector from a random peptide library displayed on an adenoviral fiber knob to overcome the limitation that many cell type-specific ligands for targeted adenovirus vectors are not known. Here we examined whether the addition of a tumor-targeting ligand to a replication-competent adenovirus ablated for naive tropism enhances its therapeutic index. First, a peptide-display adenovirus library was screened on a pancreatic cancer cell line (AsPC-1), and particular peptide sequences were selected. The replication-competent adenovirus displaying the selected ligand (AdDeltaCAR-SYE) showed higher oncolytic potency in several other pancreatic cancer cell lines as well as AsPC-1 compared with the untargeted adenovirus (AdDeltaCAR). An intratumoral injection of AdDeltaCAR-SYE significantly suppressed the growth of AsPC-1 subcutaneous tumors, and an analysis of adenovirus titer in the tumors revealed an effective replication of the virus in the tumors. Ectopic liver gene transduction following the intratumoral injection of AdDeltaCAR-SYE was not increased compared with the AdDeltaCAR. The results showed that a tumor-targeting strategy using an adenovirus library is promising for optimizing the safety and efficacy of oncolytic adenovirus therapy.
条件复制型腺病毒是一种新型的抗癌药物,旨在选择性地在肿瘤细胞中复制。然而,病毒从肿瘤泄漏到全身循环中经常导致各种器官的异位感染。因此,抑制病毒的原始嗜性并增加肿瘤靶向潜能对于确保患者安全和提高溶瘤腺病毒在临床环境中的治疗效果是必要的。我们最近开发了一种从腺病毒纤维旋钮上展示的随机肽文库中直接选择靶向载体的方法,以克服许多针对靶向腺病毒载体的细胞类型特异性配体未知的局限性。在这里,我们研究了在缺乏原始嗜性的复制型腺病毒中添加肿瘤靶向配体是否可以提高其治疗指数。首先,在胰腺癌细胞系(AsPC-1)上筛选肽展示腺病毒文库,并选择特定的肽序列。展示所选配体的复制型腺病毒(AdDeltaCAR-SYE)在其他几种胰腺癌细胞系以及 AsPC-1 中的溶瘤效力均高于未靶向的腺病毒(AdDeltaCAR)。与 AdDeltaCAR 相比,AdDeltaCAR-SYE 的肿瘤内注射显著抑制了 AsPC-1 皮下肿瘤的生长,并且对肿瘤中腺病毒滴度的分析表明病毒在肿瘤中有效复制。与 AdDeltaCAR 相比,肿瘤内注射 AdDeltaCAR-SYE 后异位肝脏基因转导没有增加。结果表明,使用腺病毒文库的肿瘤靶向策略有望优化溶瘤腺病毒治疗的安全性和疗效。